Preconditioning Mesenchymal Stem Cells to Improve Transplant Tolerance

Abstract

an immunophenotype and expressed IDO (AEIFN-g) consistent with ISCT guidelines, with no significant differences compared to CTR (Figure 1; p>0.05). Following co-culture at varying concentrations, both CTR and SCD MSCs equally suppressed proliferation of CTR and SCD T cells in a dosedependent manner (Figure 2; p>0.05). While a significant difference was detected between CTR and SCD MSC suppression of 3 rd party T cells (p<0.05), this was dependent on inclusion of SCD001, which had robust suppression of T cell proliferation; when this sample was removed, no significant difference was found (p>0.05). By Fluidigm array, no differences in the expression of hematopoietic factors were seen between SCD and CTR MSCs (p>0.05); stimulation with IFN

Overview of the Therapeutic Applications of Stem Cell–Derived Exosomes: A Research and Commercial Perspective

“…Published patents have included generation and isolation practices of MSC‐derived exosomes (De La Rosa et al., 2018; Mitsialis & Kourembanas, 2021; Shpall et al. 2019; Wobma Kanal, & Vunjak‐Novakovic, 2019) and their use in the treatment of soft tissue damage (Ludlow, Buerhrer, & Pieraccini, 2017), neurological disorders (Offen & Perets, 2019), diabetes mellitus (Westenfelder & Gooch, 2020), and inflammatory lung diseases (Mitsialis, Lee, & Kourembanas, 2014).…”